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Molecularly Imprinted Nanoparticles for Inhibiting Ribonuclease 
in Reverse Transcriptase Polymerase Chain Reaction 
Xiaotong Feng, Jon Ashley, Tongchang Zhou, Arnab Halder, Yi Sun* 
 
Molecularly imprinted nanoparticles (nanoMIPs) are 
synthesized via a solid-phase approach using RNase as the 
template. The feasibility of employing the nanoMIPs as 
RNase inhibitor is successfully demonstrated in reverse 
transcriptase polymerase chain reaction (RT-PCR) assays, 
suggesting the tailor-made nanomaterials are very promising 
for use in routine biological assays. 
 
Reverse transcriptase polymerase chain reaction (RT-PCR) is 
considered as the gold standard in quantifying RNA. It has found 
widespread use in food and environmental analysis as well as 
medical diagnostics. 1–4 However, the accuracy of RT-PCR can be 
severely affected by the presence of Ribonucleases (RNases), a 
ubiquitous enzyme in living organisms that can degrade RNA and 
compromise RNA integrity.5 As such, RNase inhibitors are often 
added in RT-PCR to protect RNA from degradation by RNases.  
Small molecules such as oligomers of vinylsulfonic acid (OVS) and 
pyrophosphate-linked oligonucleotide (pdUppA-3-p) can inhibit 
RNases, but the production is difficult and they are susceptible to 
hydrolysis. 6–8 Metal ions also exhibit inhibitory effect by acting as a 
transition state analog, whereas they tend to bind with RNA which 
would interrupt the RT-qPCR assay. 9,10 The most commonly used 
RNases inhibitors are the nature/recombinant proteins which can 
form a tight 1:1 complex with RNases and render them inactive.11,12 
Despite the high efficiency, these proteins are expensive and have 
relatively short shelf-lives due to their biological origin. 
Recently, nanomaterials have been increasingly used in bioassays. A 
particularly exciting area of research is molecularly imprinted 
polymers (MIPs). Molecular imprinting is a generic approach for 
generating a polymer matrix with binding sites that are structurally 
and functionally complementary to its template.13–15 Encouraged by 
the extraordinary molecular recognition capability, many researchers 
have exploited MIPs in sample preparation and biosensing to capture 
targets ranging from small molecules to big proteins.16–18 Lately, 
some groups have reported that the MIPs could inhibit their enzyme 
templates owing to the ability to trigger specific molecular 
interactions. 19–21 A pioneer work by Cutivet et. al. indicated that 
MIP microgels imprinted for trypsin could bind the enzyme and 
significantly reduce its enzymatic activity. 19 Zhang et. al. also 
demonstrated the synthesis of hydrophilic MIP microspheres with 
trypsin inhibition potency.20 Liu et. al. showed that the MIPs could 
specifically and reversibly block the activity of  DNase I in complex 
biological samples.21 These findings suggested that MIPs possess 
enormous potential to function as a new class of enzyme inhibitors. 
This is very exciting, as compared to protein inhibitors, MIPs offer 
additional advantages including easy design, high thermal stability, 
and robustness, as well as low fabrication cost. However, up to now, the 
exploration of MIPs as enzyme inhibitors has been limited to proof-of-
concept only, and their applications in real biological reactions have 
seldom been demonstrated.   
In this study, we proposed for the first time, to use MIPs nanoparticles 
(nanoMIPs) as RNase A inhibitors in the RT-PCR assay (Fig. 1). 
The nanoMIPs were synthesized via a solid-phase approach, and 
cavities with complementary shape, size and functional groups to the 
template were formed on the surface (Fig. S1 †). They could 
interact with the RNase A at multiple binding sites which also 
include the active sites of the RNase A, thereby blocking the 
enzymatic activity and preventing RNA degradation. The 
formulation of the nanoMIPs was optimized by screening commonly 
used functional monomers. When added to the RT-PCR assay, the 
nanoMIPs managed to inhibit 10 ng of RNase A in a 10 µL-reaction. 
Moreover, the nanoMIPs did not interfere with other enzymes such 
as RNA reverse transcriptase and DNA polymerase. Since only a 
trace amount of RNase A (sub ng) is expected to be present in an 
RT-PCR reaction, the nanoMIPs could in principle replace the 
commercial recombinant protein inhibitors. With the competitive 
inhibition behavior, we believe the tailor-made nanomaterials are 
very promising for a variety of biological and biomedical 
applications. 
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Fig. 1 Schematic illustration of the use of RNase A nanoMIPs in RT-PCR assay. RNase A can degrade RNA and compromise RNA 
integrity, which severely affects the accuracy of RT-PCR (upper part). The nanoMIPs have cavities that are complementary in shape, size 
and functional groups of RNase A. They could interact with the RNase A at multiple binding sites, thereby blocking the enzymatic activity 
and preventing RNA degradation in the RT-PCR assay (lower part). 
In this work, RNase A was used as the model template and a solid-
phase approach was chosen to synthesize the nanoMIPs (Fig. S1†). 
Traditional MIP synthesis methods, such as suspension polymerization 
and emulsion polymerization, were not suitable for this application, as the 
templates could hardly be completely removed from the nanoMIPs due 
to the equilibrium balance between the template and polymer matrix.  
The leakage of RNase A template could act as a potential source of 
contamination to the RT-PCR assay.  In contrast,  in the solid-phase 
synthesis, the template was immobilized on the surface of glass 
beads.22  The reaction mixture containing monomers, initiator and 
crosslinker was then added, and the nanoMIPs were formed around 
the RNase A template during the polymerization.   After synthesis, 
the unreacted monomers and low-affinity nanoMIPs were washed 
away, and high-affinity nanoMIPs were separated from the templates 
by a hot elution. Therefore, the resultant nanoMIPs were template-
free and endowed with homogenous and high-affinity binding sites.  
RNase A is a basic protein with an isoelectric point (pI) of 9.6 and a 
molecular weight of 13.7 kDa. It contains 19 of the 20 natural amino 
acids (excluding tryptophan) and is made up of a single polypeptide 
chain of 124 amino acid residues. The proton transfer between two 
histidines (His 12 and His 119) active sites of RNase A and 
phosphodiester bond and phosphate group of RNA can cause 
degradation of RNA. 23 Therefore, in order to efficiently inhibit 
RNase A, it is crucial for the nanoMIPs to bind to the active sites of 
the enzyme. Since the composition of the functional monomers has a 
great impact on the binding behavior of the nanoMIPs, we 
synthesized a small library of nanoMIPs with various monomer 
ratios in order to find the optimized formulation (Table. S1†). 
Herein, N-isopropyl acrylamide (NIPAm) was employed as a 
backbone monomer. Acrylic acid (AAc) (pKa=4.7) was chosen to 
interact with positively-charged residues (e.g. α-amino group from 
histidine). N-tert-Butylactylamide (TBAm) was utilized to interact 
with hydrophobic residues of RNase A. Methacrylamide (AAm) was 
used to provide hydrogen bond (e.g., interacting with nitrogen in the 
imidazole ring of histidine). Their inhibitory potency towards RNase 
A was measured using the RNase A activity kit as shown in Figure. 
2a. The inhibition efficiency of nanoMIP 2 was higher than 
nanoMIP 1, suggesting that hydrophobic interactions via TBAm 
were beneficial for inactivating the RNase A. Though RNase A is a 
polar molecule, the major and the minor dimers are made up mainly 
of apolar side chains. 24 The hydrophobic interactions with TBAm 
could enhance the binding specificity, which in turn contributed to 
the inhibition efficiency. By further decreasing the amount of AAc 
and increasing the amount of TBAm, nanoMIP 3 showed better 
inhibition than nanoMIP 2. This might be because the non-specific 
electrostatic interaction caused by the negatively-charged AAc was 
much reduced. Moreover, nanoMIP 4 was further improved by 
adding 5% AAm. This was possibly attributed to the fact that AAm 
could provide hydrogen interactions with the histidine at the active 
sites of the RNase A. Taken together, these results indicated that the 
proper combination of hydrophobic, hydrogen and negatively-
charged functional groups is essential for forming nanoMIPs with 
high inhibition efficiency. Therefore, nanoMIP 4 with the 
composition of 50 mol% NIPAm, 5 mol% AAm, 5 mol% AAc, 38 
mol% TBAm and 2 mol% BIS (N,N′-Methylenebis(acrylamide))  
was selected for the further experiments.  
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The yield, size, and morphology of nanoMIPs 4 were then 
characterized. A typical solid-phase reaction utilized 25 g glass 
beads. The amount of RNase A immobilized on per gram of glass 
beads was 6.37 nmol as determined by bicinchoninic acid assay 
(BCA)-based protein assay (Fig. S2†). The yield of high-affinity 
nanoparticles obtained was 0.58 mg g-1 glass beads or 14.5 mg per 
reaction. The scanning electron microscopy (SEM) image of 
nanoMIP 4 showed spherical nanoparticles with sizes ranging from 
100 to 200 nm (Fig. S3a†), which was smaller than that measured 
by dynamic light scattering (DLS) (Fig. S3b†). This could be due to 
the fact that the nanoparticles shrank upon drying.  
We further investigated the binding capacity, kinetics, and selectivity 
of nanoMIP 4. The binding capacity of the nanoMIP for RNase A 
was determined by equilibrium binding assays. The isotherm curve 
was shown in Fig. S4a. The adsorption of RNase A to nanoMIPs 4 
(5 mg mL-1) increased rapidly with the increment of RNase A 
concentration. The saturation was reached at 25 µg mL-1. Based on 
the Scatchard plot (Fig. S5), the dissociation constant Kd and Qmax 
were calculated to be 3.2 µg mL-1(237 nM) and 4.98 µg mg-1 (364 
nmol g-1), respectively. The binding capacity of the nanoMIP was  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 (a) Inhibitory effect of nanoMIPs (different monomer 
compositions) towards RNase A. (b) Comparison of the inhibitory 
potency of the protein inhibitor and the nanoMIP 4. Insert refers to 
the magnification of the plot in the range of 50 pg to 5000 pg. 
 
relatively low when compared to MIPs synthesized by other 
methods. This was because, for solid-phase synthesis, only one 
imprinted cavity was formed on the surface of single nanoMIPs. The 
binding kinetics of the nanoMIP was shown in Fig. S4b.  The 
binding between RNase A (5 µg mL-1) and nanoMIPs 4 (5 mg mL-1) 
was measured at different time points (5−60 min). It could be seen 
that binding took about 15 min to reach 90% of the equilibrium 
level. To investigate the selectivity of RNase A nanoMIPs, lysozyme 
(MW = 14.3 kDa, pI = 9.3), β-Lactoglobulin (MW = 18.4 kDa, pI = 
5.1) and hemoglobin (MW = 64.5 kDa, pI = 6.8) were selected as 
reference proteins. The results illustrated that the nanoMIP had 
higher selectivity towards RNase A, indicating the binding sites 
created on the nanoMIP were specific to RNase A (Fig. S4c). 
Next, we compared the inhibition efficiency of nanoMIP 4 with the 
commercial protein RNase A inhibitor. The nanoMIP 4 (5 mg mL-1) 
or protein inhibitor (10 U µL-1) was incubated with RNase A at 
different concentrations (0 to 10 ng µL-1) in 2 µL of PBS buffer. The 
amount of active RNase A was determined using the RNase A 
activity kit as plotted in Fig. 2b. When the total amount of RNase A 
was less than 10 ng, the nanoMIPs was able to achieve similar 
inhibition efficiency as the protein inhibitor, and > 90% of RNase A 
was inactive. The results confirmed that with the cavities of 
complementary shape, size, and chemical functional groups, the 
nanoMIPs could recognize and block the active sites of RNase A. 
However, it was also noted that when the RNase A was raised to 20 
ng (10 µg mL-1), the non-inhibited RNase A rose remarkably for the 
nanoMIPs while the increase was insignificant for the protein 
inhibitor. The inhibition assay showed that 2.5 ng of RNase A was 
still active, which corresponded well with the binding capacity of the 
nanoMIPs. The binding isotherm curve (Fig. S4a†) showed that 10 
µg of nanoMIPs was able to bind 17.5 ng of RNase A at the 
concentration of 10 µg mL-1, therefore 2.5 ng of RNase A remained 
unbound. The inhibitory potency of the nanoMIPs could be 
improved by either increasing the concentration of nanoMIPs or 
further optimizing the compositions and categories of functional 
monomers used to synthesize the nanoMIPs. 
Finally, the feasibility of applying the nanoMIPs to inhibit RNase A 
was tested in RT-PCR assays. The RT-PCR was carried out using 
the miRCURY LNA™ Universal RT microRNA PCR kit. The 
synthetic microRNA UniSp6 was used as the template to avoid any 
prior RNase A contamination, and the two-step assay was based on 
universal reverse transcription followed by real-time PCR 
amplification. One µl of RNase A at different concentrations (0 to 50 
ng µL-1) were spiked into a 10 µL-RT reaction mixture. For 
comparison, three types of RT assays were performed: 1) without 
any inhibitors; 2) with protein inhibitor; 3) with nanoMIPs. Real-
time PCR was then carried out using the cDNA products from the 
RT step, and the reaction was detected by accumulation of a 
fluorescent signal as shown in Fig. 3. The Ct value, which is defined 
as the number of cycles required for the fluorescent signal to cross 
the threshold, is summarised in Table. 1. As the Ct levels are 
inversely proportional to the amount of target nucleic acid in the 
sample, they were used to evaluate the inhibitory effect of the 
nanoMIP and protein inhibitor. 
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Fig. 3. The real-time RT-PCR assays with (a) different concentrations of RNase A without adding inhibitors; (b) different concentrations of 
RNase A mixed with protein inhibitor; (c) different concentrations of RNase A mixed with nanoMIPs. Y-axis represents fluorescence 
intensity after each PCR cycle, which corresponds to the amount of PCR products in the reaction tube. 
 For the RT assay without any inhibitors, the Ct value did not show a 
significant change when less than 100 pg of RNase A was added, 
indicating that abundant target microRNA remained intact in the 
sample. As RNase A was above 1 ng, the Ct increased considerably, 
showing that a large amount of microRNA was degraded by the 
RNase A (Fig. 3a). Whereas when the protein inhibitor was mixed 
with RNase A, the Ct value showed a remarkable right-shift at 50 ng 
of RNase A (Fig. 3b), suggesting that the protein inhibitor could 
efficiently inhibit at least 20 ng RNase A. In comparison, when the 
nanoMIP was applied, a notable change in Ct value occurred at 20 
ng of RNase A (Fig. 3c), implying the nanoMIP successfully 
inhibited 10 ng of RNase A. These results agreed well with the 
inhibiton test which showed that the nanoMIP was able to achieve 
comparable inhibition efficiency as the protein inhibitor if the total 
amount of RNase A was less than 10 ng. It was also worth noting 
that the positive control of all the three types of RT assays showed a 
similar Ct value, indicating that nanoMIP did not interfere with other  
Table 1. Ct values for the three types of RT-PCR assays. 
 
RNase A concentration 
(pg µL -1) 
                                  Ct value 
Without RNase A 
inhibitor 
Protein 
inhibitor 
MIP 
inhibitor 
0 14.6 14.3 14.5 
50 14.5 14.7 14.8 
100 15.3 15 14.7 
1000 18.8 15.1 15.2 
5000 31.5 15 15.1 
10000 NA 15.3 15.4 
20000 NA 16.2 28.7 
50000 NA 31 N/A 
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enzymes present in the reaction mixture such as reverse transcriptase 
and DNA polymerase. 
Conclusions 
In summary, water-compatible RNase A nanoMIPs were 
successfully synthesized by solid phase method with an optimized 
composition. These results suggested that the nanoMIPs have high 
binding specificity towards RNase A, and could effectively prevent 
degradation of RNA. To the best of our knowledge, this was the first 
time that the nanoMIPs were used as RNase A inhibitor in RT-PCR 
assays. Further work will focus on improving the binding capacity of 
RNase A by changing the compositions and categories of functional 
monomers, which will make it truly comparable with commercial 
protein inhibitor. We anticipate that the nanoMIPs, as a low-cost and 
thermal-stable enzyme inhibitor, will become a valuable tool in 
routine biological assays. 
Conflicts of interest 
 There are no conflicts to declare. 
 
Acknowledgments 
This work was financially supported by the Villum Fonden, 
Denmark, Project No. 13153. 
 
Notes and references  
1 I. Van Der Auwera, D. Peeters, I. H. Benoy, H. J. Elst, S. J. 
Van Laere, A. Prové, H. Maes, P. Huget, P. Van Dam, P. B. 
Vermeulen and L. Y. Dirix, British Journal of Cancer, 2010, 
102, 276–284. 
2 F. Postollec, H. Falentin, S. Pavan, J. Combrisson and D. 
Sohier, Food Microbiology, 2011, 28, 848–861. 
3 D. Knezevic, A. D. Goddard, N. Natraj, D. B. Cherbavaz, K. 
M. Clark-Langone, J. Snable, D. Watson, S. M. Falzarano, C. 
Magi-Galluzzi, E. A. Klein and C. Quale, BMC Genomics, 
2013, 14, 1–12. 
4 T. Svingen, H. Letting, N. Hadrup, U. Hass and A. M. 
Vinggaard, PeerJ, 2015, 3, e855. 
5 M. Saramago, C. Bárria, R. F. dos Santos, I. J. Silva, V. Pobre, 
S. Domingues, J. M. Andrade, S. C. Viegas and C. M. 
Arraiano, Current Opinion in Microbiology, 2014, 18, 105–
115. 
6 G. I. Yakovlev, V. A. Mitkevich and A. A. Makarov, 
Molecular Biology, 2006, 40, 867–874. 
7 B. D. Smith, M. B. Soellner and R. T. Raines, Journal of 
Biological Chemistry, 2003, 278, 20934–20938. 
8 S. P. Velagapudi, Y. Luo, T. Tran, H. S. Haniff, Y. Nakai, M. 
Fallahi, G. J. Martinez, J. L. Childs-DIsney and M. D. Disney, 
ACS Central Science, 2017, 3, 205–216. 
9 E. Rosta, W. Yang and G. Hummer, Journal of the American 
Chemical Society, 2014, 136, 3137–3144. 
10 K. J. Thompson, J. Zong and G. A. Mackie, Journal of 
Bacteriology, 2015, 197, 477–482. 
11 F. Sorgeloos, B. K. Jha, R. H. Silverman and T. Michiels, PLoS 
Pathogens, PLoS pathogens,2013,9,6. 
12 A. Mizrak, M. F. Bolukbasi, G. B. Ozdener, G. J. Brenner, S. 
Madlener, E. P. Erkan, T. Ströbel, X. O. Breakefield and O. 
Saydam, Molecular Therapy, 2013, 21, 101–108. 
13 H. Zhang, Polymer (United Kingdom), 2014, 55, 699–714. 
14 W. Ji, M. Zhang, Q. Gao, L. Cui, L. Chen and X. Wang, 
Analytical and Bioanalytical Chemistry, 2016, 408, 5319–
5328. 
15 J. Ashley, Y. Shukor and I. E. Tothill, The Analyst, 2016, 141, 
6463–6470. 
16 X. Feng, J. Ashley, T. Zhou, A. Halder and Y. Sun, RSC 
Advances, 2018, 8, 2365–2372. 
17 Y. Hu, J. Pan, K. Zhang, H. Lian and G. Li, TrAC - Trends in 
Analytical Chemistry, 2013, 43, 37–52. 
18 H.-B. Zheng, J.-Z. Mo, Y. Zhang, Q. Gao, J. Ding, Q.-W. Yu 
and Y.-Q. Feng, Journal of Chromatography A, 2014, 1329, 
17–23. 
19 A. Cutivet, C. Schembri, J. Kovensky and K. Haupt, 
J.Am.Chem.Soc, 2009, 131, 2–5. 
20 H. Zhang, J. Jiang, H. Zhang, Y. Zhang and P. Sun, ACS 
Macro Letters, 2013, 2, 566–570. 
21 Y. Liu, S. Wang, C. Zhang, X. Su, S. Huang and M. Zhao, 
Analytical Chemistry, 2013, 85, 4853–4857. 
22 F. Canfarotta, A. Poma, A. Guerreiro and S. Piletsky, Nature 
protocols, 2016, 11, 443. 
23 D. Gagné and N. Doucet, FEBS Journal, 2013, 280, 5596–
5607. 
24 Y. Liu, G. Gotte, M. Libonati and D. Eisenberg, Nature 
Structural Biology, 2001, 8, 211–214. 
 
 
 
Page 5 of 6 Analyst
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
A
na
ly
st
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
16
 M
ay
 2
01
8.
 D
ow
nl
oa
de
d 
by
 D
TU
 L
ib
ra
ry
 o
n 
19
/0
5/
20
18
 1
1:
35
:2
2.
 
View Article Online
DOI: 10.1039/C8AN00711J
Table of Entry 
 
 
We showed that molecularly imprinted nanoparticles (nanoMIPs) synthesized for RNase A could efficiently inhibit the activities of 
the RNase in reverse transcriptase polymerase chain reactions (RT-PCR), demonstrating that the tailor-made nanomaterials are 
very promising for use in routine biological assays. 
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